Developing a new method to sequence proteins using nanopore technology
Long-read single-molecule protein sequencing on an array of unfoldase-coupled nanopores
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10892827
This study is working on a new way to read the full structure of proteins using special technology, which could help us better understand how proteins work and change in diseases like cancer, ultimately benefiting patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10892827 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a platform that can directly sequence full-length protein strands using advanced nanopore technology. By utilizing unfoldase motors, the researchers aim to drive proteins through nanopores, allowing for the identification of their primary sequences and post-translational modifications at a single-molecule level. This approach seeks to overcome the limitations of current proteomic technologies, providing a more efficient and accurate method for protein analysis. Patients may benefit from improved understanding of protein functions and modifications related to various diseases, including cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions linked to protein abnormalities, such as certain cancers or genetic disorders.
Not a fit: Patients with conditions unrelated to protein sequencing or those who do not have protein-related diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostics and targeted therapies for diseases related to protein dysfunction.
How similar studies have performed: While nanopore sequencing has shown promise in DNA/RNA applications, this specific approach for protein sequencing is relatively novel and has not been extensively tested.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NIVALA, JEFFREY MATTHEW — UNIVERSITY OF WASHINGTON
- Study coordinator: NIVALA, JEFFREY MATTHEW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.